Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.
Decay-accelerating factor (DAF, CD55) is a glycophosphatidyl inositol-anchored glycoprotein that regulates the activity of C3 and C5 convertases. In addition to understanding the mechanism of complement inhibition by DAF through structural studies, there is also an interest in the possible therapeut...
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
2004
|
| _version_ | 1826298070770384896 |
|---|---|
| author | White, J Lukacik, P Esser, D Steward, M Giddings, N Bright, JR Fritchley, S Morgan, B Lea, S Smith, G Smith, R |
| author_facet | White, J Lukacik, P Esser, D Steward, M Giddings, N Bright, JR Fritchley, S Morgan, B Lea, S Smith, G Smith, R |
| author_sort | White, J |
| collection | OXFORD |
| description | Decay-accelerating factor (DAF, CD55) is a glycophosphatidyl inositol-anchored glycoprotein that regulates the activity of C3 and C5 convertases. In addition to understanding the mechanism of complement inhibition by DAF through structural studies, there is also an interest in the possible therapeutic potential of the molecule. In this report we describe the cloning, expression in Escherichia coli, isolation and membrane-targeting modification of the four short consensus repeat domains of soluble human DAF with an additional C-terminal cysteine residue to permit site-specific modification. The purified refolded recombinant protein was active against both classical and alternative pathway assays of complement activation and had similar biological activity to soluble human DAF expressed in Pichia pastoris. Modification with a membrane-localizing peptide restored cell binding and gave a large increase in antihemolytic potency. These data suggested that the recombinant DAF was correctly folded and suitable for structural studies as well as being the basis for a DAF-derived therapeutic. Crystals of the E. coli-derived protein were obtained and diffracted to 2.2 A, thus permitting the first detailed X-ray crystallography studies on a functionally active human complement regulator protein with direct therapeutic potential. |
| first_indexed | 2024-03-07T04:41:14Z |
| format | Journal article |
| id | oxford-uuid:d1b907a3-72a7-47ba-a8b2-fec362bfc35f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:41:14Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:d1b907a3-72a7-47ba-a8b2-fec362bfc35f2022-03-27T07:58:55ZBiological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d1b907a3-72a7-47ba-a8b2-fec362bfc35fEnglishSymplectic Elements at Oxford2004White, JLukacik, PEsser, DSteward, MGiddings, NBright, JRFritchley, SMorgan, BLea, SSmith, GSmith, RDecay-accelerating factor (DAF, CD55) is a glycophosphatidyl inositol-anchored glycoprotein that regulates the activity of C3 and C5 convertases. In addition to understanding the mechanism of complement inhibition by DAF through structural studies, there is also an interest in the possible therapeutic potential of the molecule. In this report we describe the cloning, expression in Escherichia coli, isolation and membrane-targeting modification of the four short consensus repeat domains of soluble human DAF with an additional C-terminal cysteine residue to permit site-specific modification. The purified refolded recombinant protein was active against both classical and alternative pathway assays of complement activation and had similar biological activity to soluble human DAF expressed in Pichia pastoris. Modification with a membrane-localizing peptide restored cell binding and gave a large increase in antihemolytic potency. These data suggested that the recombinant DAF was correctly folded and suitable for structural studies as well as being the basis for a DAF-derived therapeutic. Crystals of the E. coli-derived protein were obtained and diffracted to 2.2 A, thus permitting the first detailed X-ray crystallography studies on a functionally active human complement regulator protein with direct therapeutic potential. |
| spellingShingle | White, J Lukacik, P Esser, D Steward, M Giddings, N Bright, JR Fritchley, S Morgan, B Lea, S Smith, G Smith, R Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title_full | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title_fullStr | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title_full_unstemmed | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title_short | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. |
| title_sort | biological activity membrane targeting modification and crystallization of soluble human decay accelerating factor expressed in e coli |
| work_keys_str_mv | AT whitej biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT lukacikp biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT esserd biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT stewardm biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT giddingsn biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT brightjr biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT fritchleys biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT morganb biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT leas biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT smithg biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli AT smithr biologicalactivitymembranetargetingmodificationandcrystallizationofsolublehumandecayacceleratingfactorexpressedinecoli |